Innovation in Developing and Transition Countries
Show Less

Innovation in Developing and Transition Countries

Edited by Alexandra Tsvetkova, Jana Schmutzler, Marcela Suarez and Alessandra Faggian

This edited volume offers a multidisciplinary perspective on innovation challenges and innovative practices in the context of developing and transition countries. The contributions mostly embrace a national innovation system approach in an attempt to understand innovation processes and their implications at both macro and micro levels.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 4: The role of public policies in building up a national pharmaceutical innovation system in Tunisia: challenges after the Jasmine Revolution

Nejla Yacoub

Abstract

The economic literature emphasizes the importance of technological innovation as a key determinant of structural competitiveness, both for firms and countries. Building such competitiveness has long been linked to the developed world. In the last two decades, however, several developing countries have increasingly worked on setting-up innovation systems to strengthen their structural competitiveness in many sectors. This chapter explores the role of Tunisian public policies in building up the national pharmaceutical innovation system and the challenges faced by the country after the ‘Jasmine Revolution’. We try to answer two central questions: (1) have the pharmaceutical innovation policies in Tunisia been efficient before the Jasmine Revolution? (2) to what extent would the sought-after political democracy enforce a genuine innovation take-off in the Tunisian pharmaceutical sector? To answer these questions, we first evaluate innovation activities and processes in the Tunisian pharmaceutical industry before the revolution. This evaluation is based on an analysis of the national sectoral innovation system and on a survey of the Tunisian pharmaceutical firms. We then explore the public policies set up since the Jasmine Revolution and discuss their expected impact on the prospects of pharmaceutical innovation catch-up in Tunisia.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.


Further information

or login to access all content.